These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36561534)

  • 1. Optimal predictive probability designs for randomized biomarker-guided oncology trials.
    Zabor EC; Kaizer AM; Pennell NA; Hobbs BP
    Front Oncol; 2022; 12():955056. PubMed ID: 36561534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts.
    Zabor EC; Kaizer AM; Garrett-Mayer E; Hobbs BP
    JCO Precis Oncol; 2022 Mar; 6():e2100390. PubMed ID: 35385345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
    Berry SM; Broglio KR; Groshen S; Berry DA
    Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint.
    Yin G; Chen N; Lee JJ
    Stat Biosci; 2018 Aug; 10(2):420-438. PubMed ID: 30559900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
    Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
    Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative models and randomization techniques for Bayesian response-adaptive randomization with binary outcomes.
    Proper J; Connett J; Murray T
    Clin Trials; 2021 Aug; 18(4):417-426. PubMed ID: 33926267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker-based Bayesian randomized clinical trial design for identifying a target population.
    Sugitani Y; Morita S; Nakakura A; Yamamoto H
    Stat Med; 2023 Jul; 42(16):2797-2810. PubMed ID: 37078122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A confidence function-based posterior probability design for phase II cancer trials.
    Shan M
    Pharm Stat; 2021 May; 20(3):485-498. PubMed ID: 33336856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A predictive probability design for phase II cancer clinical trials.
    Lee JJ; Liu DD
    Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
    Guo B; Li Y
    BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
    Kaizer A; Zabor E; Nie L; Hobbs B
    PLoS One; 2022; 17(8):e0272367. PubMed ID: 35917296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial design with Bayesian adaptive randomization and predictive probability.
    Yin G; Chen N; Lee JJ
    J R Stat Soc Ser C Appl Stat; 2012 Mar; 61(2):219-35. PubMed ID: 24259753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II trials: a long-term investment with promising returns.
    Sharma MR; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials.
    Cabarrou B; Leconte E; Sfumato P; Boher JM; Filleron T
    BMC Med Res Methodol; 2022 Oct; 22(1):278. PubMed ID: 36289451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.